Cibus (CBUS) Operating Income (2016 - 2026)
Cibus (CBUS) posted Operating Income of -$22.6 million for Q4 2025, down 46.22% sequentially from -$15.4 million in Q3 2025, and down 25.24% YoY from -$30.2 million in Q4 2024.
Cibus (CBUS) Operating Income (2016 - 2026) Analysis & Trends
Cibus has reported Operating Income for 10 years, with the latest figure at -$22.6 million in Q4 2025.
- Quarterly Operating Income fell 25.24% year-over-year to -$22.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$97.5 million (up 62.26% YoY) and the FY2025 annual result came in at -$97.5 million, up 62.26% from the prior year.
- Operating Income retreated to -$22.6 million in Q4 2025 per CBUS's latest filing, from -$15.4 million in the prior quarter.
- Over five years, Operating Income peaked at -$3.3 million in Q4 2022 and troughed at -$269.3 million in Q4 2023.
- A 5-year average of -$36.3 million and a median of -$16.7 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income plunged 8028.95% in 2023, then surged 93.31% in 2024.
- Over 5 years, Operating Income stood at -$6.7 million in 2021, then surged by 50.63% to -$3.3 million in 2022, then slumped by 8028.95% to -$269.3 million in 2023, then soared by 93.31% to -$18.0 million in 2024, then dropped by 25.24% to -$22.6 million in 2025.
- According to Business Quant data, Operating Income over the past three periods registered -$22.6 million, -$15.4 million, and -$17.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | -12.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.93 Mn |
| Dec 31, 2025 | -22.57 Mn |
| Sep 30, 2025 | -15.44 Mn |
| Jun 30, 2025 | -17.95 Mn |
| Mar 31, 2025 | -41.57 Mn |
| Dec 31, 2024 | -18.02 Mn |
| Sep 30, 2024 | -200.44 Mn |
| Jun 30, 2024 | -21.48 Mn |
| Mar 31, 2024 | -18.45 Mn |
| Dec 31, 2023 | -269.31 Mn |
| Sep 30, 2023 | -25.80 Mn |
| Jun 30, 2023 | -19.31 Mn |
| Mar 31, 2023 | -4.46 Mn |
| Dec 31, 2022 | -3.31 Mn |
| Sep 30, 2022 | -6.20 Mn |
| Jun 30, 2022 | -6.77 Mn |
| Mar 31, 2022 | -6.09 Mn |
| Dec 31, 2021 | -6.71 Mn |
| Sep 30, 2021 | -6.96 Mn |
| Jun 30, 2021 | -5.98 Mn |